Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

• Status: Recruiting
• Trial end date: 2022-05-12
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

• Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE)

Secondary Objectives:

• Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity)

• Assess the effect of SAR443122 on CLE induced itch and overall pain

• Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo

• Assess the effect of SAR443122 on the CLASI components score

• Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE)

• Assess oral cavities for patients with oral lesions

• Assess the disease specific quality of life (QoL)

• Assess the safety and tolerability of SAR443122 in patients with CLE

• Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi

Criteria

Inclusion criteria :

• Participants with cutaneous lupus erythematosus either in the form of discoid/chronic cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus for at least 3 months before Screening.

• Participants with histologically confirmed and documented diagnosis within one year prior to Screening or during Screening period prior to randomization.

• Active cutaneous lupus erythematosus skin lesions and a Cutaneous Erythematosus.

• Disease Area and Severity Index activity (CLASI-A) ≥10 both at Screening and Baseline.

• Participant who is candidate for systemic treatment per Investigator's judgement.

Exclusion criteria:

• Systemic lupus erythematosus according to the 2012 SLICC criteria with major organ involvement.

• Suspected or proven drug induced lupus erythematosus, including patients with positive antihistone autoantibody tests.

• Autoimmune disease(s) other than systemic lupus erythematosus.

• Active skin diseases that may interfere with the study or study assessments.

• Exclusion related to tuberculosis, non-tuberculous mycobacterial infections, HIV, HBV, HCV, Herpes zoster, COVID-19 and other recurrent or recent serious infections.

• Prolonged QTcF ≥ 450 ms (by Frederica formulation) or clinically significant findings on electrocardiogram (ECG).

• Cannot avoid excessive UV exposure 4 weeks prior to baseline and during the study. Routine sun exposure through work are permitted but requires the use of sun block to sun exposed areas for at least 4 weeks prior to baseline and during the study.

• Concomitant treatment with topical immunosuppressants beyond a stable regimen of low to medium potency topical corticosteroids and/or topical calcineurin inhibitors during the study and two weeks before baseline visit.

• Initiation and/or changes in dosage of chloroquine/hydroxychloroquine within 12 weeks prior to Screening visit (or during Screening period) and/or the dose exceeding 2.3 mg/kg/day for chloroquine or 400 mg/day for hydroxychloroquine.

• Systemic treatments for cutaneous or systemic lupus erythematosus or immunosuppressive therapy for autoimmune disease other than the study medication.

• Systemic corticosteroids treatment <4 weeks before baseline visit.

• Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study.

• Laboratory abnormalities at the Screening visit.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.